These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35169044)

  • 1. Copper chelation in patients with hypertrophic cardiomyopathy.
    Reid A; Miller C; Farrant JP; Polturi R; Clark D; Ray S; Cooper G; Schmitt M
    Open Heart; 2022 Feb; 9(1):. PubMed ID: 35169044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.
    Farrant J; Dodd S; Vaughan C; Reid A; Schmitt M; Garratt C; Akhtar M; Mahmod M; Neubauer S; Cooper RM; Prasad SK; Singh A; Valkovič L; Raman B; Ashkir Z; Clayton D; Baroja O; Duran B; Spowart C; Bedson E; Naish JH; Harrington C; Miller CA;
    Heart; 2023 Jul; 109(15):1175-1182. PubMed ID: 37137675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced myocardial characterization in hypertrophic cardiomyopathy: feasibility of CMR-based feature tracking strain analysis in a case-control study.
    Yang L; Zhang L; Cao S; Gao C; Xu H; Song T; Zhang X; Wang K
    Eur Radiol; 2020 Nov; 30(11):6118-6128. PubMed ID: 32588208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMR feature tracking strain patterns and their association with circulating cardiac biomarkers in patients with hypertrophic cardiomyopathy.
    Cavus E; Muellerleile K; Schellert S; Schneider J; Tahir E; Chevalier C; Jahnke C; Radunski UK; Adam G; Kirchhof P; Blankenberg S; Lund GK; Avanesov M; Patten M
    Clin Res Cardiol; 2021 Nov; 110(11):1757-1769. PubMed ID: 33779809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between left ventricular outflow tract obstruction and left ventricular shape in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study.
    Martin R; Lairez O; Boudou N; Méjean S; Lhermusier T; Dumonteil N; Berry M; Cognet T; Massabuau P; Elbaz M; Rousseau H; Galinier M; Carrié D
    Arch Cardiovasc Dis; 2013; 106(8-9):440-7. PubMed ID: 23906680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy.
    Neisius U; Myerson L; Fahmy AS; Nakamori S; El-Rewaidy H; Joshi G; Duan C; Manning WJ; Nezafat R
    PLoS One; 2019; 14(8):e0221061. PubMed ID: 31433823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy.
    Latif SR; Nguyen VQ; Peters DC; Soufer A; Henry ML; Grunseich K; Testani J; Hur DJ; Huber S; Mojibian H; Dicks D; Sinusas AJ; Meadows JL; Papoutsidakis N; Jacoby D; Baldassarre LA
    Int J Cardiovasc Imaging; 2019 Jul; 35(7):1309-1318. PubMed ID: 30790116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm.
    Rodrigues JC; Rohan S; Ghosh Dastidar A; Harries I; Lawton CB; Ratcliffe LE; Burchell AE; Hart EC; Hamilton MC; Paton JF; Nightingale AK; Manghat NE
    Eur Radiol; 2017 Mar; 27(3):1125-1135. PubMed ID: 27368925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Myocardial Disarray in Patients With Hypertrophic Cardiomyopathy and Ventricular Arrhythmias.
    Ariga R; Tunnicliffe EM; Manohar SG; Mahmod M; Raman B; Piechnik SK; Francis JM; Robson MD; Neubauer S; Watkins H
    J Am Coll Cardiol; 2019 May; 73(20):2493-2502. PubMed ID: 31118142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
    Cooper GJ; Young AA; Gamble GD; Occleshaw CJ; Dissanayake AM; Cowan BR; Brunton DH; Baker JR; Phillips AR; Frampton CM; Poppitt SD; Doughty RN
    Diabetologia; 2009 Apr; 52(4):715-22. PubMed ID: 19172243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrelationship between the Myocardial Mass, Fibrosis, BNP, and Clinical Outcomes in Hypertrophic Cardiomyopathy.
    Miyaji Y; Iwanaga Y; Nakamura T; Yasuda M; Kawamura T; Miyazaki S
    Intern Med; 2016; 55(10):1261-8. PubMed ID: 27181530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Young patients with hypertrophic cardiomyopathy, but not subjects at risk, show decreased myocardial perfusion reserve quantified with CMR.
    Gyllenhammar T; Fernlund E; Jablonowski R; Jögi J; Engblom H; Liuba P; Arheden H; Carlsson M
    Eur Heart J Cardiovasc Imaging; 2014 Dec; 15(12):1350-7. PubMed ID: 25139907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4D flow MRI and T1 -Mapping: Assessment of altered cardiac hemodynamics and extracellular volume fraction in hypertrophic cardiomyopathy.
    van Ooij P; Allen BD; Contaldi C; Garcia J; Collins J; Carr J; Choudhury L; Bonow RO; Barker AJ; Markl M
    J Magn Reson Imaging; 2016 Jan; 43(1):107-14. PubMed ID: 26227419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular structure and diastolic function by cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.
    Chacko BR; Karur GR; Connelly KA; Yan RT; Kirpalani A; Wald R; Jimenez-Juan L; Jacob JR; Deva DP; Yan AT
    Indian Heart J; 2018; 70(1):75-81. PubMed ID: 29455792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging.
    Esposito A; De Cobelli F; Perseghin G; Pieroni M; Belloni E; Mellone R; Canu T; Gentinetta F; Scifo P; Chimenti C; Frustaci A; Luzi L; Maseri A; Maschio AD
    Heart; 2009 Mar; 95(3):228-33. PubMed ID: 18708417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of cardiac magnetic resonance-based markers in patients with hypertrophic cardiomyopathy.
    Dohy Z; Szabo L; Toth A; Czimbalmos C; Horvath R; Horvath V; Suhai FI; Geller L; Merkely B; Vago H
    Int J Cardiovasc Imaging; 2021 Jun; 37(6):2027-2036. PubMed ID: 33555536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications.
    Raman B; Ariga R; Spartera M; Sivalokanathan S; Chan K; Dass S; Petersen SE; Daniels MJ; Francis J; Smillie R; Lewandowski AJ; Ohuma EO; Rodgers C; Kramer CM; Mahmod M; Watkins H; Neubauer S
    Eur Heart J Cardiovasc Imaging; 2019 Feb; 20(2):157-167. PubMed ID: 30358845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of left ventricular dyssynchrony on gated myocardial perfusion SPECT analysis with extent of late gadolinium enhancement on cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.
    Yuki H; Utsunomiya D; Shiraishi S; Takashio S; Sakamoto F; Tsuda N; Oda S; Kidoh M; Nakaura T; Tsujita K; Yamashita Y
    Heart Vessels; 2018 Jun; 33(6):623-629. PubMed ID: 29230571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of global myocardial mechanics in hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking. Relations to left ventricular hypertrophy and fibrosis.
    Hinojar R; Fernández-Golfín C; González-Gómez A; Rincón LM; Plaza-Martin M; Casas E; García-Martín A; Fernandez-Mendez MA; Esteban A; Nacher JJJ; Zamorano JL
    Int J Cardiol; 2017 Dec; 249():467-472. PubMed ID: 29121751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.